A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and tirzepatide in patients with type 2 diabetes (T2D). The study found that […]
A new analysis of the SELECT trial – the largest and longest clinical trial to date examining the cardiovascular benefits of semaglutide (a medication used to support weight […]
GLP-1 receptor agonist drugs protect against diabetic retinopathy, a common complication of diabetes that can lead to sight loss, suggests new research being presented at the annual meeting […]
The new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), is proving remarkably effective at helping individuals lose weight. However, a new population-wide study being presented at […]
Worldwide, 60 million people suffer from heart failure (HF). Heart failure with preserved ejection fraction (HFpEF) is the most common form of HF, especially among people with obesity […]
Bariatric surgery is usually effective on its own for weight loss, but an increasing proportion of patients who undergo bariatric surgery start taking one of the new glucagon-like […]
Individuals who take liraglutide or semaglutide for weight loss reduce their alcohol consumption by almost two-thirds in four months, new research being presented at this year’s European Congress […]
A new head-to-head study of tirzepatide versus semaglutide for weight loss in people living with obesity, but not diabetes, shows that over 72 weeks tirzepatide results in an […]
Results from the ACHIEVE-1 trial show that treatment with orforglipron was associated with weight loss ranging from 4.7 – 7.9% (4.4 – 7.3 Kg) of body weight in […]
Pharmacist Deborah Evans runs a weight-management clinic at Remedi Health in Winchester. She has helped many people to lose weight and improve their health using the GLP-1 receptor […]
The blockbuster drug semaglutide, better known as Ozempic for diabetes and Wegovy for obesity, could also help people cut down on their alcohol intake, according to new research […]
Researchers report that patients treated with semaglutide have achieved a significantly lower risk of developing Alzheimer’s disease compared to those exposed to seven other anti-diabetic medications, including other […]
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare news and e-journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our email journals and publications.
